Journal article
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
Abstract
AIMS: Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding. The aim of this study was to estimate the individual lifetime treatment benefit and harm of adding low-dose rivaroxaban to aspirin in patients with stable cardiovascular disease.
METHODS AND RESULTS: Patients with established CVD from the COMPASS trial (n = 27 390) …
Authors
de Vries TI; Eikelboom JW; Bosch J; Westerink J; Dorresteijn JAN; Alings M; Dyal L; Berkowitz SD; van der Graaf Y; Fox KAA
Journal
European Heart Journal, Vol. 40, No. 46, pp. 3771–3778a
Publisher
Oxford University Press (OUP)
Publication Date
December 7, 2019
DOI
10.1093/eurheartj/ehz404
ISSN
0195-668X